Longeveron Inc. announced that the United States Patent and Trademark Office has granted a patent for methods of treating aging-related frailty in patients with inflammaging using its proprietary mesenchymal stem cell $(MSC)$ therapy. The patent, which is valid through 2038, covers the administration of isolated allogeneic MSCs to address symptoms such as weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss in older individuals. The company's lead MSC therapy, laromestrocel, has shown positive initial results in two clinical trials targeting aging-related frailty.